	anti-CCP	anti-MCV	Citl+Citl	Citl+Hcitl	HcitI+CitI	Hcitl+Hcitl	Citll+Citll	CitII+HcitII	HcitII+CitII	Hcitll+Hcitll	erosion	RF	gender
1	+	+	+	-	-	+	+	-	-	-	+/-	+	f
2	+	+	+	-	- +	-	+	-	-	-	+	+ +	m f
4	-	-	-	-	-	-	-	-	-	-	-	-	f
5	+	+	+	-	-	+	+	-	-	+	-	+	m
6	+	-	-	-	-	-	-	-	-	-	+	+	f
7	-	-	-	+	-	-	+	+	+	-	-	-	f
8 9	+	+	+	+	-	-	-	-	-	-	+	+	f f
9 10	-	+	-	-	-	-	-	-	-	-	+	-	f
11	-	-	-	-	-	-	-	-	-	-	+	+	f
12	-	-	-	-	-	-	-	-	-	+	+/-	+/-	f
13	-	-	-	-	-	-	-	-	-	-	-	-	m
14	-+	+	-	-	-	-	+	-	+	-	+/-	+	m
15 16	-	+	+	-	-	+	-	-	-	+	+/- -	+	f f
17	-	-	-	-	-	-	-	-	-	-	-	+/-	f
18	+	+	-	-	-	-	+	-	-	-	+	+	f
19	-	-	-	-	-	-	-	-	-	-			f
20	-	-	-	-	-	-	-	-	-	-	-,	-	f
21 22	+	+	+	+	+	+	+	+	-	+	+/- +	+	m m
23	-	-	-	-	-	-	-	-	-	-	-	-	f
24	+	+	+	-	-	-	-	-	-	-	-	+	f
25	+	+	+	+	-	-	+	+	-	+	+	+	f
26	-	-	-	-	-	-	-	-	-	-	-	-	m
27 28	+	+	-	-	-	-	-	-	-	-	+	+	m f
28 29	+	+	+	-	- +	+	+	-	-	- +	+	+	m
30	-	-	-	-	-	-	-	-	-	-	-	-	f
31	+	+	+	-	-	+	+	+	-	+	+	+	f
32	+	-	+	-	-	-	+	+	-	-	-	+/-	f
33	+	+	+	-	-	+	+	-	-	+	-	+	m
34 35	- +	+	+	+	-	-	+	+	-	-	- +	- +	f f
36	+	+	+	-	-	-	+	+	-	-	+	+/-	f
37	+	+	+	-	-	+	+	-	-	+	+	+	f
38	-	-	-	-	-	-	-	-	-	-	+	+	f
39	+	+	+	-	+	-	+	-	-	-	-	+	m
40 41	-	-	+	-	-	-	-	-	-	-	-	-	f 
42	+	+	+	-	+	-	-	-	-	-	+	+ +	m f
43	+	+	+	-	-	-	-	-	-	-	+	-	m
44	+	+	+	-	+	-	-	-	-	-			f
45	-	-	-	-	-	-	-	-	-	-	-	-	m
46 47	-	-	-	-	-	-	-	+	-	+	+ +/-	-	f f
48	+	+	-	-	-	-	+	-	-	+	+/-	+	m
49	-	-	-	-	-	-	-	-	-	-	-	-	m
50	-	-	-	+	-	-	-	-	-	-	-	-	f
51	-	-	-	-	-	-	-	-	-	-	-	-	m
52 52	+	+	+	-	-	-	-	+	-	-	+	+	f m
53 54	+	+	+	-	-	+	+	-	+	-	+	+	m m
55	+	+	+	-	-	-	+	-	-	-	+	+	m
56	+	+	+	-	-	+	+	-	-	+	+	-	f
57	+	+	-	-	-	-	+	-	-	-	+		f
58	+	+	+	-	-	+	+	-	-	-	+	-	m
59 60	-	-	-	-	-	-	-	-	-	-	- +	- +	f f
61	+	+	+	-	+	+	+	-	-	+	+/-	+	m
62	+	+	+	+	+	+	-	-	-	-	+/-	+	f
63	+	+	+	-	+	-	-	-	-	-	+	+	m
64	+	+	+	-	-	+	+	-	-	-	+	+	f
65	-	+	+	-	+	-	+	+	-	-	+/-	+	m
66 67	+	+	+	-	-	+	+	-	-	+	+	+	m m
68	+	+	+	-	-	+	+	-	+	-	-	+/-	m
69	-	-	-	-	-	-	-	-	+	-	-	-	f
70	-	-	-	+	-	-	-	-	-	-	-	+/-	m
71	-	-	-	-	-	-	-	-	-	-	-	-	f
72	-		-	-	. <del>-</del>	-	-	- ·	-	- ·		+	m

Additional patient data. Anti-CCP and anti-MCV results are from direct ELISA, positivity was defined by the calibration series supplied by the manufacturer. For the other assays, results from inhibition-ELISAs are shown. Positivity was defined by inhibition values exceeding the mean + 2SD of controls. Erosions and RF were categorized as +, - or +/-. The borderline cases were defined as positive in logistic regression analysis. Gender is shown by one letter abbreviations: m, male and f, female. For the abbreviations of collagen telopeptide antigens, see Table 1.